Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 55.47% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 55.47% YoY), while the FY2025 annual figure was $1.9 million, up 24.95% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $2.4 million, up from $1.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $5.0 million in Q3 2023, with the low at $403000.0 in Q2 2022.
• The 5-year median for Other Non-Current Assets is $1.5 million (2024), against an average of $2.2 million.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets soared 923.97% in 2023, then plunged 75.49% in 2025.
• Rigel Pharmaceuticals' Other Non-Current Assets stood at $640000.0 in 2022, then jumped by 377.34% to $3.1 million in 2023, then slumped by 50.02% to $1.5 million in 2024, then increased by 24.95% to $1.9 million in 2025, then climbed by 23.53% to $2.4 million in 2026.
• Business Quant data shows RIGL's Other Non-Current Assets at $2.4 million in Q1 2026, $1.9 million in Q4 2025, and $1.2 million in Q3 2025.